Literature DB >> 19450312

Atrial fibrillation (acute onset).

Gregory Y H Lip1, Timothy Watson.   

Abstract

INTRODUCTION: Risk factors for acute atrial fibrillation include increasing age, cardiovascular disease, alcohol, diabetes, and lung disease. Acute atrial fibrillation increases the risk of stroke and heart failure. Acute atrial fibrillation resolves spontaneously within 24-48 hours in over 50% of people, however many people will require interventions to control heart rate or restore sinus rhythm. METHODS AND OUTCOMES: We conducted a systematic review and aimed to answer the following clinical questions: What are the effects of interventions: to prevent embolism; for conversion to sinus rhythm; and to control heart rate in people with recent onset atrial fibrillation (within 7 days) who are haemodynamically stable? We searched: Medline, Embase, The Cochrane Library and other important databases up to October 2007 (Clinical Evidence reviews are updated periodically, please check our website for the most up-to-date version of this review). We included harms alerts from relevant organisations such as the US Food and Drug Administration (FDA) and the UK Medicines and Healthcare products Regulatory Agency (MHRA).
RESULTS: We found 28 systematic reviews, RCTs, or observational studies that met our inclusion criteria. We performed a GRADE evaluation of the quality of evidence for interventions.
CONCLUSIONS: In this systematic review we present information relating to the effectiveness and safety of the following interventions: amiodarone, antithrombotic treatment before cardioversion, digoxin, diltiazem, direct current cardioversion, flecainide, propafenone, quinidine, sotalol, timolol, and verapamil.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19450312      PMCID: PMC2907989     

Source DB:  PubMed          Journal:  BMJ Clin Evid        ISSN: 1462-3846


  64 in total

1.  Hemodynamic effects of an irregular sequence of ventricular cycle lengths during atrial fibrillation.

Authors:  D M Clark; V J Plumb; A E Epstein; G N Kay
Journal:  J Am Coll Cardiol       Date:  1997-10       Impact factor: 24.094

2.  Comparison between propafenone and digoxin administered intravenously to patients with acute atrial fibrillation. PAFIT-3 Investigators. The Propafenone in Atrial Fibrillation Italian Trial.

Authors:  L Bianconi; M Mennuni
Journal:  Am J Cardiol       Date:  1998-09-01       Impact factor: 2.778

3.  Comparison of intravenous diltiazem and verapamil for the acute treatment of atrial fibrillation and atrial flutter.

Authors:  B G Phillips; A J Gandhi; C A Sanoski; V L Just; J L Bauman
Journal:  Pharmacotherapy       Date:  1997 Nov-Dec       Impact factor: 4.705

4.  Atrial fibrillation in elite athletes.

Authors:  F Furlanello; A Bertoldi; M Dallago; A Galassi; F Fernando; A Biffi; P Mazzone; C Pappone; S Chierchia
Journal:  J Cardiovasc Electrophysiol       Date:  1998-08

5.  Conversion of recent-onset atrial fibrillation to sinus rhythm: effects of different drug protocols.

Authors:  G Boriani; M Biffi; A Capucci; G Botto; T Broffoni; M Ongari; G Trisolino; I Rubino; M Sanguinetti; A Branzi; B Magnani
Journal:  Pacing Clin Electrophysiol       Date:  1998-11       Impact factor: 1.976

Review 6.  Rate issues in atrial fibrillation: consequences of tachycardia and therapy for rate control.

Authors:  B Schumacher; B Lüderitz
Journal:  Am J Cardiol       Date:  1998-10-16       Impact factor: 2.778

7.  Prevalence, incidence, prognosis, and predisposing conditions for atrial fibrillation: population-based estimates.

Authors:  W B Kannel; P A Wolf; E J Benjamin; D Levy
Journal:  Am J Cardiol       Date:  1998-10-16       Impact factor: 2.778

8.  Propafenone for the treatment of supraventricular tachycardia and atrial fibrillation: a meta-analysis.

Authors:  S C Reimold; W H Maisel; E M Antman
Journal:  Am J Cardiol       Date:  1998-10-16       Impact factor: 2.778

9.  Intravenous propafenone for converting recent onset atrial fibrillation in emergency departments: a randomized placebo-controlled multicenter trial. FAPS Investigators Study Group.

Authors:  G Ganau; T Lenzi
Journal:  J Emerg Med       Date:  1998 May-Jun       Impact factor: 1.484

10.  Comparison of sotalol with digoxin-quinidine for conversion of acute atrial fibrillation to sinus rhythm (the Sotalol-Digoxin-Quinidine Trial).

Authors:  M O Halinen; M Huttunen; S Paakkinen; L Tarssanen
Journal:  Am J Cardiol       Date:  1995-09-01       Impact factor: 2.778

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.